Watchlist
ITGR · Integer Holdings Corporation
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Current thesis
Integer Holdings Corporation’s $127.00 cash acquisition by KKR remains a completion thesis, strengthened by the 2026-09-03 merger proxy. Completion by year-end 2026 would settle the case; a daily close below $118 invalidates it.
Kill line
A daily close below $118 invalidates the completion thesis; a disclosed termination or company announcement moving completion beyond year-end 2026 would independently contradict the case.
Pick status
Open commitment catalyst in 10dscored if the kill line above fires How this is scored →Latest analysis and events for ITGR —
As of 13 September 2026, the latest FrontierPicks analysis for Integer Holdings Corporation (ITGR): Integer Holdings Corporation’s $127.00 cash acquisition by KKR remains a completion thesis, strengthened by the 2026-09-03 merger proxy. Completion by year-end 2026 would settle the case; a daily close below $118 invalidates it.
Kill line: A daily close below $118 invalidates the completion thesis; a disclosed termination or company announcement moving completion beyond year-end 2026 would independently contradict the case.
Next dated event on file: — catalyst in 10d.
Current Thesis
Integer Holdings Corporation’s thesis remains completion of KKR’s $127.00 cash acquisition by year-end 2026; the September merger filings strengthen that case, while a daily close below $118 invalidates it. The transaction was announced on 2026-08-03 with committed financing and no financing condition. Completion, rather than another earnings-driven valuation increase, is the outcome being forecast. KKR announcement
The 2026-09-03 preliminary merger proxy supersedes the prior note’s missing-paperwork concern. It discloses Hart-Scott-Rodino (HSR) antitrust filings on 2026-08-31 and scheduled waiting-period expiry on 2026-09-30. These are measured procedural advances; interpreting them as stronger completion evidence is an inference, not regulatory clearance. Preliminary proxy
The narrative is maturing — the agreement became public on 2026-08-03, Benchmark moved to Hold on 2026-08-14, and the supplied adjusted market close reached $126.00 on 2026-09-11. The evidence now concerns execution of an announced transaction, rather than discovery of a new operating story.
Bullish and bearish views on Integer Holdings Corporation
The model's bull view on Integer Holdings Corporation (ITGR), in brief: A funded agreement remains operative. The 2026-08-03 announcement specified $127.00 per share in cash, approximately $5.7 billion of enterprise value and unanimous board approval. Those terms support the completion case, subject to the published price invalidation and required… The bear view: The vote remains undated. The preliminary proxy filed on 2026-09-03 leaves the special-meeting and record dates blank. Filing the document resolves the earlier absence of a proxy, but does not establish shareholder approval. Preliminary proxy Standalone revenue was still… Both cases follow in full.
Bull Case
- A funded agreement remains operative. The 2026-08-03 announcement specified $127.00 per share in cash, approximately $5.7 billion of enterprise value and unanimous board approval. Those terms support the completion case, subject to the published price invalidation and required approvals. KKR announcement
- The regulatory process is observable. Ireland’s Competition and Consumer Protection Commission (CCPC) published the transaction on 2026-09-11, identifying a simplified merger review with an outcome of pending. This establishes an active review, without establishing approval. CCPC case record
Bear Case
- The vote remains undated. The preliminary proxy filed on 2026-09-03 leaves the special-meeting and record dates blank. Filing the document resolves the earlier absence of a proxy, but does not establish shareholder approval. Preliminary proxy
- Standalone revenue was still declining. Integer’s 2026-08-03 second-quarter release reported sales declining 2.6% year over year and organic sales declining 1.5%; the company also withdrew its fiscal 2026 outlook. Those reported declines do not establish an independent growth thesis if the acquisition fails.
- Consideration fixes the contractual endpoint. The 2026-08-03 agreement specifies $127.00 cash, while the supplied 2026-09-11 adjusted close is $126.00. A higher payment would require changed transaction terms or another proposal; the current agreement supplies neither. KKR announcement
Setup & Price Structure
The supplied adjusted daily series records a $126.00 close on 2026-09-11, a $126.50 trailing-year high and a three-month price increase of 38.5%. The close sits 0.4% below that high. These measurements describe strength near the contractual consideration; they do not measure completion probability.
Benchmark’s 2026-08-14 downgrade to Hold is an observable shift in analyst coverage. No current fund-flow series, retail-coverage count or moving-average level accompanies the 2026-09-11 snapshot, so a crowding verdict is unsupported. The sparse reference closes in the earlier coverage are too small a sample to establish spread stability.
Catalyst Calendar (next 30 days)
- 2026-09-24 — Irish submission deadline. The CCPC’s 2026-09-11 case record sets this deadline for third-party submissions; it is not a clearance date. CCPC case record
- 2026-09-30 — Scheduled HSR expiry. The 2026-09-03 proxy specifies 11:59 p.m. Eastern Time, subject to extension, early termination, refiling or an agreement delaying completion. Preliminary proxy
- 2026-12-31 — Completion checkpoint. This represents the end-of-2026 expectation announced on 2026-08-03, not a scheduled closing appointment. Failure to complete by then falsifies the timing component of the thesis. KKR announcement
What Would Change Our Mind
Loss of the completion structure would be registered by a daily close below $118, the research threshold established in the 2026-08-30 published note. It is an analytical invalidation level, not demonstrated chart support. A disclosed termination or a company announcement moving completion beyond year-end 2026 would independently contradict the stated case.
Correlation Notes
This is a single-name merger setup. The fixed cash terms announced on 2026-08-03 support treating transaction developments as the principal explanatory variable. The 2026-09-11 price snapshot contains no paired benchmark-return series, so it supports no measured correlation claim with medical-device equities, KKR shares or broader merger securities.
Notes
- Integer withdrew its FY2026 financial outlook on 2026-08-03 for the pendency of the KKR transaction; no company forecast exists while the merger is outstanding.
- Upside is contractually capped at $127.00 cash absent a superior proposal; the agreement carries a $154M company termination fee and a $307M parent reverse termination fee.
- Unvested RSU/PSU awards are 50% cashed out at closing and 50% remain subject to existing service vesting under the merger agreement (2026-08-03).
- NYSE-listed; the shares delist on closing, guided by the company to year-end 2026 with a merger-agreement outside date of 2027-05-02.
- Delaware Court of Chancery is the exclusive forum for certain merger-related actions under the deal documents filed 2026-08-03.
- The merger sub is Armstrong Bidco, an affiliate of funds managed by Kohlberg Kravis Roberts & Co. (8-K filed 2026-08-04).
Related · shared themes
TXG
10x Genomics, Inc.
10x Genomics' Atera recovery now needs deliveries and revenue confirmation after clearing its earlier price hurdle. Approximately 40 second-half 2026 shipments and full-year revenue of $610–630 million would substantiate the case before a weekly close below $58.57 invalidates the structure.
APGE
Apogee Therapeutics, Inc.
Apogee Therapeutics’ $135.11-per-share cash-acquisition thesis resolved with AbbVie’s completion on 2026-09-03. The 2026-09-14 Form 15 advances administrative closure, leaving no unresolved APGE acquisition catalyst.
ATAI
AtaiBeckley Inc.
AtaiBeckley's Lilly acquisition thesis resolved with completion on 2026-09-11, ending the pending-merger case. Remaining contingent payments depend on disclosed clinical and regulatory milestones; Nasdaq suspended ATAI effective 2026-09-14.
DSGR
Distribution Solutions Group, Inc.
Distribution Solutions Group’s $35.00 cash acquisition remains a completion thesis, with the minority vote and closing settling the case. HSR clearance occurred on 2026-08-20; a daily close below $33.50 invalidates the price thesis.
See also · stocks to watch